Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Kooth shares plummet after US pilot trial terminated

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Digital mental health provider Kooth (KOO:AIM) saw its shares slump after the company revealed (18 Oct) it had received a 30-day notice from the US state of Pennsylvania to terminate its pilot contract.
The contract was first signed on 11 October 2021 and was extended by a year from 30 June 2024 to June next year, whilst negotiations on a new contract were ongoing.
The company said the status of its work in the state going forward was now ‘unclear’ and it was urgently seeking clarification. Analysts at Stifel believe politics played a role and the decision was not related to the product, which received positive user feedback and utilisation.
The share-price reaction looks severe given it was worth just $3 million and paled into insignificance compared with the four-year $188 million contract signed with the state of California.
Unfortunately, on 24 October the shares fell a further 20% following publication of a newsletter article regarding Kooth’s service in California which contained ‘outdated’ information underestimating the product’s uptake and effectiveness.
Kooth has subsequently put the record straight and the shares seem to have stabilised. The company said its product has already demonstrated meaningful clinical benefits with 70% of those accessing single-session therapy reporting positive outcomes.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.